Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) made a significant announcement regarding its entry into an Agreement and Plan ...

Marinus regains ganaxolone’s commercial rights in Europe where the compound is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) ...

NEXI-001 is under clinical development by NexImmune and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a 30% phase ...

Fadraciclib is under clinical development by Cyclacel Pharmaceuticals and currently in Phase II for Pancreatic Cancer.

ORION CORPORATION PRESS RELEASE 30 DECEMBER 2024 at 14.00 EET Orion and Marinus terminate agreement for ganaxolone in Europe Orion Corporation ("Orion") and Marinus Pharmaceuticals, Inc.

Cyclins regulate steroid receptor action in cyclin-dependent kinase (CDK)-dependent and independent manners. In addition to regulating the cell cycle, cyclin A2 (CCNA2) also mediates female sex ...

Addition of the CDK 4/6 inhibitor improved progression-free survival by 15.2 months for patients with HR+/HER2+ advanced ...

In tumoral cells, the modulation of the G1/S phases of cell cycle is destabilized by amplification and high expression of cyclin E (CCNE) or by mutation or loss of retinoblastoma 1 (RB1) gene. Cancer ...

Incyclix Bio has reported outcomes from the dose escalation part of the Phase I/II INX-315-01 trial of INX-315 for breast cancer treatment.

In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a ...

Poster presentation details are below: Author: Molina et al Title: CID-078, a first-in-class oral cyclin A/B-RxL inhibitor, elicits anti-tumor activity in breast cancer patient-derived xenograft ...

1UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. 2Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, ...